Table of Contents Author Guidelines Submit a Manuscript
International Journal of Hypertension
Volume 2011, Article ID 132405, 9 pages
http://dx.doi.org/10.4061/2011/132405
Review Article

Hypertension in Chronic Kidney Disease: Navigating the Evidence

1Division of Renal Diseases, Department of Medicine, SUNY Downstate Medical Center, 450 Clarkson Avenue, Box 52, Brooklyn, NY 11203, USA
2Department of Medicine, Brooklyn Health Disparities Center, SUNY Downstate Medical Center, Brooklyn, NY 11203, USA

Received 14 February 2011; Accepted 29 March 2011

Academic Editor: Adam T. Whaley-Connell

Copyright © 2011 F. M. Tedla et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. M. Sinclair, C. G. Isles, I. Brown, H. Cameron, G. D. Murray, and J. W. Robertson, “Secondary hypertension in a blood pressure clinic,” Archives of Internal Medicine, vol. 147, pp. 1289–1293, 1987. View at Google Scholar
  2. A. S. Go, G. M. Chertow, D. Fan, C. E. McCulloch, and C. Y. Hsu, “Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization,” New England Journal of Medicine, vol. 351, no. 13, pp. 1296–1305, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. N. S. Anavekar, J. J. V. McMurray, E. J. Velazquez et al., “Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction,” New England Journal of Medicine, vol. 351, no. 13, pp. 1285–1295, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. A. S. Levey, J. Coresh, K. Bolton et al., “K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification,” American Journal of Kidney Diseases, vol. 39, no. 2, pp. S1–S266, 2002. View at Google Scholar · View at Scopus
  5. J. Coresh, E. Selvin, L. A. Stevens et al., “Prevalence of chronic kidney disease in the United States,” Journal of the American Medical Association, vol. 298, no. 17, pp. 2038–2047, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. F. Turnbull, “Effects of different blood-pressure-lowering regimens on major cardiovascular events: Results of prospectively-designed overviews of randomised trials,” Lancet, vol. 362, no. 9395, pp. 1527–1535, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. B. M. Egan, Y. Zhao, and R. N. Axon, “US trends in prevalence, awareness, treatment, and control of hypertension, 1988–2008,” Journal of the American Medical Association, vol. 303, no. 20, pp. 2043–2050, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. 8. U S Renal Data System, USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Bethesda, Md, USA, 2010.
  9. N. Ridao, J. Luño, S. García De Vinuesa, F. Gómez, A. Tejedor, and F. Valderrábano, “Prevalence of hypertension in renal disease,” Nephrology Dialysis Transplantation, vol. 16, no. 1, pp. 70–73, 2001. View at Google Scholar · View at Scopus
  10. P. Muntner, A. Anderson, J. Charleston et al., “Hypertension awareness, treatment, and control in adults with CKD: results from the chronic renal insufficiency cohort (CRIC) study,” American Journal of Kidney Diseases, vol. 55, no. 3, pp. 441–451, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. P. Muntner, S. E. Judd, M. Krousel-Wood, W. M. McClellan, and M. M. Safford, “Low medication adherence and hypertension control among adults with CKD: data from the REGARDS (Reasons for Geographic and Racial Differences in Stroke) study,” American Journal of Kidney Diseases, vol. 56, pp. 447–457, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. J. J. Snyder and A. J. Collins, “KDOQI hypertension, dyslipidemia, and diabetes care guidelines and current care patterns in the united states CKD population: National health and nutrition examination survey 1999-2004,” American Journal of Nephrology, vol. 30, no. 1, pp. 44–54, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. P. A. Sarafidis, S. Li, S. C. Chen et al., “Hypertension awareness, treatment, and control in chronic kidney disease,” American Journal of Medicine, vol. 121, no. 4, pp. 332–340, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. F. Bangash and R. Agarwal, “Masked hypertension and white-coat hypertension in chronic kidney disease: A meta-analysis,” Clinical Journal of the American Society of Nephrology, vol. 4, no. 3, pp. 656–664, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. R. Agarwal and R. R. Lewis, “Prediction of hypertension in chronic hemodialysis patients,” Kidney International, vol. 60, no. 5, pp. 1982–1989, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. R. Agarwal, A. R. Nissenson, D. Batlle, D. W. Coyne, J. R. Trout, and D. G. Warnock, “Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States,” American Journal of Medicine, vol. 115, no. 4, pp. 291–297, 2003. View at Publisher · View at Google Scholar · View at Scopus
  17. R. Cocchi, E. D. Esposti, A. Fabbri et al., “Prevalence of hypertension in patients on peritoneal dialysis: results of an Italian multicentre study,” Nephrology Dialysis Transplantation, vol. 14, no. 6, pp. 1536–1540, 1999. View at Publisher · View at Google Scholar · View at Scopus
  18. F. Tedla, R. Hayashi, S. I. McFarlane, and M. O. Salifu, “Hypertension after renal transplant,” Journal of Clinical Hypertension, vol. 9, no. 7, pp. 538–545, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. K. L. Lynn, “Hypertension and survival in hemodialysis patients,” Seminars in Dialysis, vol. 17, no. 4, pp. 270–274, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. G. M. Chertow, N. W. Levin, G. J. Beck et al., “In-center hemodialysis six times per week versus three times per week,” New England Journal of Medicine, vol. 363, no. 24, pp. 2287–2300, 2010. View at Publisher · View at Google Scholar · View at PubMed
  21. B. L. Kasiske, S. Anjum, R. Shah et al., “Hypertension after kidney transplantation,” American Journal of Kidney Diseases, vol. 43, no. 6, pp. 1071–1081, 2004. View at Google Scholar · View at Scopus
  22. G. Opelz and B. Döhler, “Improved long-term outcomes after renal transplantation associated with blood pressure control,” American Journal of Transplantation, vol. 5, no. 11, pp. 2725–2731, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. A. C. Guyton, T. G. Coleman, D. B. Young, T. E. Lohmeier, and J. W. DeClue, “Salt balance and long-term blood pressure control,” Annual Review of Medicine, vol. 31, pp. 15–27, 1980. View at Google Scholar · View at Scopus
  24. J. E. Hall, “The kidney, hypertension, and obesity,” Hypertension, vol. 41, no. 3, pp. 625–633, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. J. J. Curtis, R. G. Luke, and H. P. Dustan, “Remission of essential hypertension after renal transplantation,” New England Journal of Medicine, vol. 309, no. 17, pp. 1009–1015, 1983. View at Google Scholar · View at Scopus
  26. B. R. Widgren, H. Herlitz, T. Hedner et al., “Blunted renal sodium excretion during acute saline loading in normotensive men with positive family histories of hypertension,” American Journal of Hypertension, vol. 4, no. 7 I, pp. 570–578, 1991. View at Google Scholar · View at Scopus
  27. G. Keller, G. Zimmer, G. Mall, E. Ritz, and K. Amann, “Nephron number in patients with primary hypertension,” New England Journal of Medicine, vol. 348, no. 2, pp. 101–108, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. E. Saad, B. Charra, and D. S. C. Raj, “Hypertension control with daily dialysis,” Seminars in Dialysis, vol. 17, no. 4, pp. 295–298, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. A. I. Günal, S. Duman, M. Özkahya et al., “Strict volume control normalizes hypertension in peritoneal dialysis patients,” American Journal of Kidney Diseases, vol. 37, no. 3, pp. 588–593, 2001. View at Google Scholar · View at Scopus
  30. N. Vasavada and R. Agarwal, “Role of excess volume in the pathophysiology of hypertension in chronic kidney disease,” Kidney International, vol. 64, no. 5, pp. 1772–1779, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. K. E. Kim, G. Onesti, A. B. Schwartz, J. L. Chinitz, and C. Swartz, “Hemodynamics of hypertension in chronic end-stage renal disease,” Circulation, vol. 46, no. 3, pp. 456–464, 1972. View at Google Scholar · View at Scopus
  32. P. Weidmann, M. H. Maxwell, A. N. Lupu, A. J. Lewin, and S. G. Massry, “Plasma renin activity and blood pressure in terminal renal failure,” New England Journal of Medicine, vol. 285, no. 14, pp. 757–762, 1971. View at Google Scholar · View at Scopus
  33. E. D. Vaughan Jr., R. M. Carey, C. R. Ayers, and M. J. Peach, “Hemodialysis-resistant hypertension: Control with an orally active inhibitor of angiotensin-converting enzyme,” Journal of Clinical Endocrinology and Metabolism, vol. 48, no. 5, pp. 869–871, 1979. View at Google Scholar · View at Scopus
  34. R. A. Augustyniak, M. Tuncel, W. Zhang, R. D. Toto, and R. G. Victor, “Sympathetic overactivity as a cause of hypertension in chronic renal failure,” Journal of Hypertension, vol. 20, no. 1, pp. 3–9, 2002. View at Publisher · View at Google Scholar · View at Scopus
  35. A. B. Chapman, A. Johnson, P. A. Gabow, and R. W. Schrier, “The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease,” New England Journal of Medicine, vol. 323, no. 16, pp. 1091–1096, 1990. View at Google Scholar · View at Scopus
  36. D. E. Kohan, “Endothelins in the normal and diseased kidney,” American Journal of Kidney Diseases, vol. 29, no. 1, pp. 2–26, 1997. View at Google Scholar · View at Scopus
  37. M. P. Blaustein, J. Zhang, L. Chen et al., “The pump, the exchanger, and endogenous ouabain: signaling mechanisms that link salt retention to hypertension,” Hypertension, vol. 53, no. 2, pp. 291–298, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  38. N. D. Vaziri, “Effect of chronic renal failure on nitric oxide metabolism,” American Journal of Kidney Diseases, vol. 38, no. 4, pp. S74–S79, 2001. View at Google Scholar · View at Scopus
  39. J. A. Mitas, S. B. Levy, and R. Holle, “Urinary kallikrein activity in the hypertension of renal parenchymal disease,” New England Journal of Medicine, vol. 299, no. 4, pp. 162–165, 1978. View at Google Scholar · View at Scopus
  40. M. J. Dunn and V. L. Hood, “Prostaglandins and the kidney,” The American Journal of Physiology, vol. 233, no. 3, pp. 169–184, 1977. View at Google Scholar · View at Scopus
  41. N. D. Vaziri, “Roles of oxidative stress and antioxidant therapy in chronic kidney disease and hypertension,” Current Opinion in Nephrology and Hypertension, vol. 13, no. 1, pp. 93–99, 2004. View at Publisher · View at Google Scholar · View at Scopus
  42. P. G. McNally and J. Feehally, “Pathophysiology of cyclosporin A nephrotoxicity: experimental and clinical observations,” Nephrology Dialysis Transplantation, vol. 7, no. 8, pp. 791–804, 1992. View at Google Scholar · View at Scopus
  43. R. N. Foley, A. M. Murray, S. Li et al., “Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States medicare population, 1998 to 1999,” Journal of the American Society of Nephrology, vol. 16, no. 2, pp. 489–495, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  44. D. S. Keith, G. A. Nichols, C. M. Gullion, J. B. Brown, and D. H. Smith, “Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization,” Archives of Internal Medicine, vol. 164, no. 6, pp. 659–663, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  45. U.S. Renal Data System, USRDS 2008 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Md, USA, 2008.
  46. A. V. Chobanian, G. L. Bakris, H. R. Black et al., “The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report,” Journal of the American Medical Association, vol. 289, no. 19, pp. 2560–2572, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  47. A. S. Levey, M. V. Rocco, S. Anderson et al., “K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease,” American Journal of Kidney Diseases, vol. 43, no. 5, pp. S1–S290, 2004. View at Google Scholar · View at Scopus
  48. D. E. Weiner, H. Tighiouart, A. S. Levey et al., “Lowest systolic blood pressure is associated with stroke in stages 3 to 4 chronic kidney disease,” Journal of the American Society of Nephrology, vol. 18, no. 3, pp. 960–966, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  49. T. Berl, L. G. Hunsicker, J. B. Lewis et al., “Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial,” Journal of the American Society of Nephrology, vol. 16, no. 7, pp. 2170–2179, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  50. J. L. Probstfield, “Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP),” Journal of the American Medical Association, vol. 265, no. 24, pp. 3255–3264, 1991. View at Publisher · View at Google Scholar
  51. G. Viberti, C. E. Mogensen, L. C. Groop, and J. F. Pauls, “Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria,” Journal of the American Medical Association, vol. 271, no. 4, pp. 275–279, 1994. View at Publisher · View at Google Scholar
  52. G. Boner, D. J. Van Dyk, M. H. Tan et al., “Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria,” Diabetologia, vol. 39, no. 5, pp. 587–593, 1996. View at Publisher · View at Google Scholar · View at Scopus
  53. E. J. Lewis, L. G. Hunsicker, R. P. Bain, and R. D. Rohde, “The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy,” New England Journal of Medicine, vol. 329, no. 20, pp. 1456–1462, 1993. View at Publisher · View at Google Scholar · View at PubMed
  54. E. J. Lewis, L. G. Hunsicker, W. R. Clarke et al., “Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes,” New England Journal of Medicine, vol. 345, no. 12, pp. 851–860, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  55. B. M. Brenner, M. E. Cooper, D. De Zeeuw et al., “Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy,” New England Journal of Medicine, vol. 345, no. 12, pp. 861–869, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  56. R. O. Estacio, B. W. Jeffers, N. Gifford, and R. W. Schrier, “Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes,” Diabetes Care, vol. 23, no. 2, pp. B54–B64, 2000. View at Google Scholar · View at Scopus
  57. R. W. Schrier, R. O. Estacio, A. Esler, and P. Mehler, “Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes,” Kidney International, vol. 61, no. 3, pp. 1086–1097, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  58. S. Klahr, A. S. Levey, G. J. Beck et al., “The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease,” New England Journal of Medicine, vol. 330, no. 13, pp. 877–884, 1994. View at Publisher · View at Google Scholar · View at PubMed
  59. UK Prospective Diabetes Study Group, “Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38,” British Medical Journal, vol. 317, pp. 703–713, 1999. View at Google Scholar
  60. A. I. Adler, I. M. Stratton, H. A. W. Neil et al., “Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study,” British Medical Journal, vol. 321, no. 7258, pp. 412–419, 2000. View at Google Scholar · View at Scopus
  61. M. A. Pohl, S. Blumenthal, D. J. Cordonnier et al., “Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: Clinical implications and limitations,” Journal of the American Society of Nephrology, vol. 16, no. 10, pp. 3027–3037, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  62. M. J. Sarnak, T. Greene, X. Wang et al., “The effect of a lower target blood pressure on the progression of kidney disease: Long-term follow-up of the modification of diet in renal disease study,” Annals of Internal Medicine, vol. 142, no. 5, pp. 342–351, 2005. View at Google Scholar · View at Scopus
  63. W. C. Cushman, G. W. Evans, R. P. Byington et al., “Effects of intensive blood-pressure control in type 2 diabetes mellitus,” New England Journal of Medicine, vol. 362, no. 17, pp. 1575–1585, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  64. G. Remuzzi, “Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy,” Lancet, vol. 349, no. 9069, pp. 1857–1863, 1996. View at Publisher · View at Google Scholar
  65. P. Ruggenenti, A. Perna, G. Loriga et al., “Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial,” Lancet, vol. 365, no. 9463, pp. 939–946, 2005. View at Publisher · View at Google Scholar · View at PubMed
  66. P. K. T. Li, C. B. Leung, K. M. Chow et al., “Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study,” American Journal of Kidney Diseases, vol. 47, no. 5, pp. 751–760, 2006. View at Publisher · View at Google Scholar · View at PubMed
  67. J. T. Wright Jr., G. Bakris, T. Greene et al., “Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial,” Journal of the American Medical Association, vol. 288, no. 19, pp. 2421–2431, 2002. View at Publisher · View at Google Scholar
  68. L. J. Appel, J. T. Wright Jr., T. Greene et al., “Intensive blood-pressure control in hypertensive chronic kidney disease,” New England Journal of Medicine, vol. 363, no. 10, pp. 918–929, 2010. View at Publisher · View at Google Scholar · View at PubMed
  69. G. Maschio, D. Alberti, G. Janin et al., “Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency,” New England Journal of Medicine, vol. 334, no. 15, pp. 939–945, 1996. View at Publisher · View at Google Scholar · View at PubMed
  70. R. Schrier, K. McFann, A. Johnson et al., “Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: results of a seven-year prospective randomized study,” Journal of the American Society of Nephrology, vol. 13, no. 7, pp. 1733–1739, 2002. View at Publisher · View at Google Scholar · View at Scopus
  71. R. Kunz, C. Friedrich, M. Wolbers, and J. F. E. Mann, “Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin-angiotensin system on proteinuria in renal disease,” Annals of Internal Medicine, vol. 148, no. 1, pp. 30–48, 2008. View at Google Scholar · View at Scopus
  72. S. Yusuf, K. K. Teo, J. Pogue et al., “Telmisartan, ramipril, or both in patients at high risk for vascular events,” New England Journal of Medicine, vol. 358, no. 15, pp. 1547–1559, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  73. S. D. Navaneethan, S. U. Nigwekar, A. R. Sehgal, and G. F. M. Strippoli, “Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis,” Clinical Journal of the American Society of Nephrology, vol. 4, no. 3, pp. 542–551, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  74. H. H. Parving, F. Persson, J. B. Lewis, E. J. Lewis, and N. K. Hollenberg, “Aliskiren combined with losartan in type 2 diabetes and nephropathy,” New England Journal of Medicine, vol. 358, no. 23, pp. 2433–2446, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  75. H. H. Parving, B. M. Brenner, J. J. V. McMurray et al., “Aliskiren trial in type 2 diabetes using cardio-renal endpoints (ALTITUDE): rationale and study design,” Nephrology Dialysis Transplantation, vol. 24, no. 5, pp. 1663–1671, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  76. P. A. Kalra, H. Guo, A. T. Kausz et al., “Atherosclerotic renovascular disease in United States patients aged 67 years or older: risk factors, revascularization, and prognosis,” Kidney International, vol. 68, no. 1, pp. 293–301, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  77. C. G. Missouris, T. Buckenham, F. P. Cappuccio, and G. A. MacGregor, “Renal artery stenosis: a common and important problem in patients with peripheral vascular disease,” American Journal of Medicine, vol. 96, no. 1, pp. 10–14, 1994. View at Publisher · View at Google Scholar · View at Scopus
  78. V. Chabova, A. Schirger, A. W. Stanson, M. A. McKusick, and S. C. Textor, “Outcomes of atherosclerotic renal artery stenosis managed without revascularization,” Mayo Clinic Proceedings, vol. 75, no. 5, pp. 437–444, 2000. View at Google Scholar · View at Scopus
  79. J. Webster, F. Marshall, M. Abdalla et al., “Randomised comparison of percutaneous angioplasty vs continued medical therapy for hypertensive patients with atheromatous renal artery stenosis,” Journal of Human Hypertension, vol. 12, no. 5, pp. 329–335, 1998. View at Google Scholar
  80. B. C. Van Jaarsveld, P. Krijnen, H. Pieterman et al., “The effect of balloon angioplasty on hypertension in atherosclerotic renal-artery stenosis,” New England Journal of Medicine, vol. 342, no. 14, pp. 1007–1014, 2000. View at Publisher · View at Google Scholar
  81. L. Bax, A. J. J. Woittiez, H. J. Kouwenberg et al., “Stent placement in patients with atherosclerotic renal artery stenosis and impaired renal function: a randomized trial,” Annals of Internal Medicine, vol. 150, no. 12, pp. 840–848, 2009. View at Google Scholar · View at Scopus
  82. K. Wheatley, N. Ives, R. Gray et al., “Revascularization versus medical therapy for renal-artery stenosis,” New England Journal of Medicine, vol. 361, no. 20, pp. 1953–1962, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  83. C. J. Cooper, T. P. Murphy, A. Matsumoto et al., “Stent revascularization for the prevention of cardiovascular and renal events among patients with renal artery stenosis and systolic hypertension: rationale and design of the CORAL trial,” American Heart Journal, vol. 152, no. 1, pp. 59–66, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  84. D. R. J. Kuypers, “Immunotherapy in elderly transplant recipients: a guide to clinically significant drug interactions,” Drugs and Aging, vol. 26, no. 9, pp. 715–737, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  85. R. N. Formica Jr., A. L. Friedman, M. I. Lorber, J. D. Smith, T. Eisen, and M. J. Bia, “A randomized trial comparing losartan with amlodipine as initial therapy for hypertension in the early post-transplant period,” Nephrology Dialysis Transplantation, vol. 21, no. 5, pp. 1389–1394, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  86. I. J.M. Scheffers, A. A. Kroon, J. Schmidli et al., “Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study,” Journal of the American College of Cardiology, vol. 56, no. 15, pp. 1254–1258, 2010. View at Publisher · View at Google Scholar · View at PubMed
  87. M. D. Esler, H. Krum, P. A. Sobotka et al., “Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial,” The Lancet, vol. 376, no. 9756, pp. 1903–1909, 2010. View at Publisher · View at Google Scholar